All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2009-012206-39 | A phase II randomized, open label clinical trial in high risk percutaneous coronary intervention (PCI) patients receiving standard antithrombotic treatment plus either ALX-0081 or GPIIb/IIIa inhibitor... | 2012-03-29 | due-trials |
| Reported results | 2010-019375-30 | A Phase II single blind, randomized, placebo controlled trial to study the efficacy and safety of anti-von Willebrand factor Nanobody administered as adjunctive treatment to patients with acquired thr... | 2014-03-14 | due-trials |
| Exempt, with results | 2010-022865-81 | A phase I/II, multi-center, randomized, double-blind, placebo controlled study, with a single ascending dose part followed by a multiple ascending dose part, evaluating the safety, pharmacokinetics, p... | 2012-10-02 | not-yet-due |
| Reported results | 2014-002841-23 | A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label... | 2016-03-02 | due-trials |
| Reported results | 2014-003012-36 | A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects with Moderate to Severe Rheumatoid Arthritis who are Intolerant to Methotrex... | 2016-08-08 | due-trials |
| Reported results | 2014-003033-26 | A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination with Methotrexate, in Subjects with Moderate to Se... | 2016-08-08 | due-trials |
| Reported results | 2014-003034-42 | A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis who Have Completed One ... | 2018-08-14 | due-trials |
| Reported results | 2015-000372-95 | A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate to ... | 2018-02-15 | due-trials |
| Trial is partly outside EEC, and reported results | 2015-001098-42 | A Phase III double-blind, randomized, parallel group, multicenter placebo-controlled trial to study the efficacy and safety of caplacizumab in patients with acquired thrombotic thrombocytopenic purpur... | 2017-08-16 | bad-data |
| Reported results | 2016-001503-23 | Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES) | 2020-10-23 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-001651-49 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose Ranging Study of ALX-0171 in Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection | 2018-05-25 | bad-data |
| Completed, but no date Terminated | 2017-003356-23 | A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX-0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell tran... | bad-data |